Is Angi, Inc. overvalued or undervalued?

As of 10 October 2025, the valuation grade for Angi, Inc. has moved from attractive to very attractive. The company appears to be undervalued, particularly when considering its P/E ratio of 16, which is lower than the peer average of approximately 14.77 for similar companies. Additionally, Angi's EV to EBITDA stands at 8.45, which is favorable compared to peers like EverQuote, Inc. with an EV to EBITDA of 12.11, and its PEG ratio is exceptionally low at 0.01, indicating strong growth potential relative to its price.
In comparison to its peers, Angi, Inc. shows a more attractive valuation profile, especially when contrasted with GoodRx Holdings, Inc., which is considered expensive with a P/E of 31.76. Although specific return data is not available, the overall valuation metrics suggest that Angi, Inc. is positioned well in the market, reinforcing the notion that it is undervalued relative to its peers.